


THE LEINCO LATEST



As we reflect on 2024, we are deeply grateful for the trust and partnership of our valued customers. Your dedication to advancing research and discovery inspires everything we do at Leinco Technologies. This past year has been filled with growth and innovation, from expanding our product portfolio to introducing new services designed to meet the evolving needs of the scientific community. A major milestone of 2024 was our acquisition of QED Bioscience, which has strengthened our capabilities and allowed us to better serve researchers worldwide.

Looking forward to 2025, we're thrilled to share exciting new launches, expanded product lines, and enhanced solutions tailored to accelerate your research. Whether it's through our high-purity *in vivo* antibodies, cutting-edge biosimilar products, or the latest additions to our infectious disease portfolio, our mission remains the same: to provide you with the tools you need to drive innovation and discovery. Thank you for being part of the Leinco family, and here's to another year of meaningful breakthroughs and progress!

SUPPORTING YOUR RESEARCH WITH STABLE PRICING

As we enter 2025, we remain steadfast in our commitment to supporting your groundbreaking research. To ease the financial challenges often faced in pre-clinical studies and biological research, we are keeping our *in vivo* antibody prices steady. Despite rising costs across the industry, we prioritize affordability and accessibility without compromising on quality. Our *in vivo* antibodies meet the highest purity standards, ensuring reliable performance for applications such as immunohistochemistry, flow cytometry, and animal studies. With consistent pricing and premium quality, we aim to empower your research and help drive meaningful discoveries in the year ahead. Together, let's make 2025 a year of progress and innovation!



EXPLORE
IN VIVO
ANTIBODIES!

ACCELERATE YOUR RESEARCH WITH OUR NEW CHO CELL SERVICES

Leinco Technologies offers a full suite of CHO-based services, including Antibody and Protein Production and CHO Stable Cell Line Development. Utilizing our advanced CHO GS-/- expression system, we ensure efficient, scalable production with exceptional yields of 3–6 grams per liter. From transient expression to stable cell line creation, our cGMP and ISO-certified facilities deliver high-quality solutions tailored to your research needs. Whether small-scale or large-scale production, our customizable services empower you to accelerate discovery with confidence.



[LEARN MORE](#)


LEINCO IN THE NEWS: GATES FOUNDATION GRANT

Leinco Technologies is proud to announce that we've received a \$1M Global Development grant from the Bill & Melinda Gates Foundation to develop a rapid test for measuring intestinal immunity to polio. This innovative tool will support global polio eradication efforts by providing accessible and reliable diagnostic insights for immunization campaigns.

Aligned with our commitment to advancing infectious disease research, this grant will help ensure that vital health products reach underserved communities, contributing to a polio-free future.


DIGITAL NEWSLETTER

Help us save paper by signing up to receive these newsletters directly in your inbox! Opt-in using the QR code.



TALK TO AN EXPERT

Do you have specific product related questions? Are you needing more information about our custom services? Scan the QR code to contact our sales team directly, and they'll be sure to respond in a timely manner.



FOLLOW US

Stay up to date with everything that's going on at Leinco by following our social media accounts. You'll be the first to know about new products, promotions and so much more! Scan to follow.

